Modified PEDV Spike Protein Vaccine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PEDV vaccine production methods are inefficient, and existing vaccines do not effectively protect against PEDV infection, particularly in young piglets, where the disease causes high mortality and economic loss.
Innovation Solution
Modification of the PEDV spike protein's amino acid sequence, specifically the RSX1IEDX2X3 sequence, to enhance production levels and localization, leading to improved vaccine efficacy and protection against PEDV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional PEDV vaccine production methods are used, then production levels are insufficient and vaccine efficacy is poor, but modifying the spike protein sequence increases production levels and improves protection
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence parameters of the PEDV spike protein, specifically changing residues at positions 900-901 from leucine-leucine (LL) to other amino acid combinations (e.g., LA, AL, AA, AG). This sequence modification results in improved vaccine production levels and enhanced protection against PEDV infection, resolving the contradiction between productivity and reliability.
2Reliability
If the spike protein sequence is modified to improve production, then vaccine efficacy increases, but the complexity of protein modification increases
Solution Approach 1:
The patent applies local quality by making targeted modifications only at specific local positions (900-901) within the spike protein sequence rather than modifying the entire protein. This localized approach to sequence modification achieves improved vaccine efficacy while minimizing the complexity of protein modification, as only a small segment of the protein needs to be altered.
3Productivity
If conventional vaccine approaches are used, then production is inefficient, but improving production methods increases cost and complexity
Solution Approach 1:
The patent applies parameter changes to the spike protein sequence (modifying residues at positions 900-901) to improve production efficiency. By changing these specific amino acid parameters, the vaccine production process becomes more efficient without requiring complex production methods, thus resolving the contradiction between productivity and device complexity.
Data Source
AI summary
The present invention relates to a nucleic acid molecule encoding a modified porcine epidemic diarrhea virus (PEDV) spike (S) protein and the PEDV (S) protein thereof. Further, the present invention relates to immunogenic compositions comprising said modified PEDV spike protein and methods for immunizing a subject comprising the administration of said immunogenic composition to a subject.